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To the Editor: Generalised weakness may be a common 
complaint of persons infected with HIV, but the development 
of significant proximal weakness requires specific attention. 
Polymyositis may occur in HIV infection and is readily 
treatable with prednisone. Elevated creatine kinase (CK) levels 
have been regarded as an important criterion for diagnosing 
polymyositis. A study of HIV-associated polymyositis reported 
similarly elevated CK levels to those observed in non-HIV 
settings.1 However, muscle inflammation can be associated 
with normal or near-normal CK levels. We report 4 cases of 
HIV-associated polymyositis in which the diagnosis was almost 
missed owing to the absence of raised CK levels.
Patient 1 presented with a subacute history of painful 
proximal muscle weakness and arthralgia (Table I). The CK 
level was normal, but electromyography (EMG) showed 
an active myopathic process and a muscle biopsy revealed 
features of polymyositis. She responded to prednisone but 
relapsed clinically within 3.5 months of weaning from the 
steroids. Re-introduction of prednisone 30 mg daily, with 
subsequent weaning, led to a durable clinical response. Patient 
2 presented with a diarrhoeal illness and 2 weeks of proximal 
muscle weakness. Stool microscopy revealed Cryptosporidium 
cysts. She was rehydrated and antiretroviral therapy was 
commenced with resolution of the diarrhoea. Despite adequate 
rehydration and normal electrolyte levels she remained too 
weak to walk without assistance. Examination confirmed a 
proximal myopathy with normal reflexes and normal findings 
on sensory examination, and EMG and muscle biopsy showed 
features of polymyositis. Her power improved substantially 
on prednisone therapy. Patients 3 and 4 both presented with 
a subacute history of proximal weakness. EMG revealed an 
active myopathic process in both as well as polymyositis on 
both muscle biopsies. Patient 3’s weakness resolved completely 
within 2 months on prednisone 60 mg. The clinician attending 
patient 4 assessed the low CK level as suggestive of ‘burnt out’ 
myositis and decided against steroid therapy. The patient was 
commenced on antiretrovirals and within 3 months her power 
had almost completely normalised.
Discussion
HIV-associated polymyositis has the same clinical, 
electromyographic and histological features as polymyositis in 
HIV-negative subjects.2 However, in our 4 patients with HIV-
associated polymyositis, normal CK levels delayed the clinical 
diagnosis of an inflammatory myositis. Although EMG and 
muscle biopsy showed evidence of polymyositis, we feel that it 
is important to highlight the importance of a normal CK level 
in this setting, as many patients may not have access to either 
EMG or histological examinations. Indeed, in a retrospective 
review of the clinical and laboratory findings of all the muscle 
biopsies performed at Groote Schuur Hospital from January 
2003 to June 2009, and limiting the analysis to those with 
clinical probable polymyositis, we found that the CK levels 
at presentation were considerably lower in the HIV-positive 
compared with the HIV-negative cohort. As an example, the 
median CK level in the HIV-positive cohort was less than half 
that in the HIV-negative cohort (manuscript in preparation). 
CK levels relate to the amount of enzyme released by the 
muscle cells, and their measurement is the most frequently 
used laboratory test screening for inflammatory myositis. CK 
levels are usually raised at least 3- to 4-fold in polymyositis.3 
However, an inflammatory myopathy on muscle biopsy may 
be associated with a CK level within the normal range, such as 
in childhood-onset dermatomyositis,4 inclusion body myositis 
and even polymyositis, although the latter accounted for <15% 
of a recent Mayo clinic series.3 Interestingly, patients with 
active rheumatoid arthritis without myositis have lower (by 
half) CK levels than normal controls, although their muscle 
aldolase levels are higher than controls.5 It has been suggested 
that an inhibitor, such as enzyme-binding immunoglobulins, 
could be present in the serum of subjects during systemic 
inflammation that may falsely ‘normalise’ the CK level,6 and 
indeed CK levels were found to be reduced after therapeutic 
administration of intravenous hyperimmune globulin, whereas 
placebo did not have this effect, irrespective of the auto-
immune disease treated.7 An alternative explanation for the low 
CK levels is that a generalised inflammatory state may result 
in post-transcriptional modification and enhanced degradation 
of CK. CK is an unstable enzyme and vulnerable to numerous 
post-transcriptional changes in the setting of generalised 
inflammation.8 The thiol groups of CK are susceptible to 
oxidation, CK may be glycated, and it can be deactivated 
by the plasma enzyme carboxypeptidase N (summarised in 
Delanghe and De Buyzere8). Enhanced rates of CK destruction 
in the setting of infection and inflammation have indeed been 
shown in vitro.8 HIV infection is characterised by background 
inflammation resulting in, for example, polyclonal activation of 
B lymphocytes,9 and these effects on CK activity have not been 
investigated.
Polymyositis is the most common HIV-associated muscle 
disease, although in rare cases uncomplicated myalgias, 
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asymptomatic elevation of CK and rhabdomyolysis may also 
be encountered.2 In a series of HIV-associated polymyositis, 10 
of 13 cases developed symptoms on ART,1 whereas all 4 of our 
patients were ART naïve. The majority of those patients, much 
like ours, responded to prednisone treatment. The decision to 
treat with immunosuppressives in the setting of HIV infection 
involves a complex balancing act to try to regain control of 
the HIV-induced immune dysregulation. Indeed, in patient 4 
the beneficial effect of ART appeared to be sufficient to regain 
control of the auto-immune process.
We highlight the fact that a patient with HIV-associated 
polymyositis may have normal serum CK levels, and in this 
setting one should perform an EMG and/or a muscle biopsy 
or at least assess other muscle enzyme levels such as serum 
aldolase and myoglobin.6 
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Table I. Clinical and laboratory characteristics of 4 patients with HIV-associated polymyositis with normal or near-normal 
creatine kinase levels
     Patient 1  Patient 2  Patient 3  Patient 4
Age (yrs), gender    29, F  39, F  35, F  22, F
Duration of symptoms (mo.)   3   0.5   2   7 
Concomitant medications   Nil  Co-trimoxazole Nil  Nil
Antiretrovirals at onset of weakness   No  No  No  No
Shoulder abduction (MRC grade)*  4–  4–  4–  3
Hip flexion power (MRC grade)*  2  4–  4–  3
Potassium (mmol/l) (N 3.3 - 3.5)  N  3.3  N  N
TSH     N  N  N  N
CD4+ count, cells/µl   389  10  83  190
Initial CK levels (IU/l) (N 26 - 140)  91  102  89  199
N = normal range; * = the weakest muscle group.
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